Phase 3 Safety and Imaging Study of AI-700 in Patients With Suspected Coronary Artery Disease Undergoing Coronary Angiography
|Coronary Artery Disease||Procedure: AI-700 contrast-enhanced echocardiography||Phase 3|
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
|Official Title:||A Phase 3, International, Multicenter, Open-Label, Dual-Injection, Echocardiographic Imaging and Safety Study in Patients With Suspected Ischemic Heart Disease Undergoing Diagnostic Coronary Angiography (Real-Time Assessment of Myocardial Perfusion With Echocardiography: RAMP 2)|
- Accuracy, sensitivity, and specificity of AI-700 ECHO in assessing CAD
- Safety of AI-700 administered IV to suspected CAD patients
|Study Start Date:||December 2003|
|Estimated Study Completion Date:||June 2006|
Assessment of myocardial perfusion has been demonstrated to provide both diagnostic and prognostic value to patients with ischemic heart disease by allowing the clinician to assess the hemodynamic significance of coronary artery disease (CAD). The primary objective of the clinical development program for AI-700 is to demonstrate the safety and efficacy of AI-700 as an intravenous ultrasound contrast agent in patients with suspected myocardial perfusion defects.
The patient population is comprised of patients being evaluated for inducible ischemia and indicated for coronary angiography. The primary study objective was to determine the accuracy, sensitivity, and specificity of AI-700-enhanced echocardiographic imaging for detecting CAD, using coronary angiography/left ventriculography (ANGIO/LVG) as the reference standard.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00156845
|United States, Massachusetts|
|Watertown, Massachusetts, United States, 02472|